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Tissue Engineering Strategies for Myocardial Regeneration:
Acellular Versus Cellular Scaffolds?
Maribella Domenech, PhD,1 Lilliana Polo-Corrales, PhD,1,2
Jaime E. Ramirez-Vick, PhD,1,3 and Donald O. Freytes, PhD4,5
Heart disease remains one of the leading causes of death in industrialized nations with myocardial infarction
(MI) contributing to at least one fifth of the reported deaths. The hypoxic environment eventually leads to
cellular death and scar tissue formation. The scar tissue that forms is not mechanically functional and often
leads to myocardial remodeling and eventual heart failure. Tissue engineering and regenerative medicine
principles provide an alternative approach to restoring myocardial function by designing constructs that will
restore the mechanical function of the heart. In this review, we will describe the cellular events that take place
after an MI and describe current treatments. We will also describe how biomaterials, alone or in combination
with a cellular component, have been used to engineer suitable myocardium replacement constructs and how
new advanced culture systems will be required to achieve clinical success.
Keywords: cardiac tissue engineering, cardiac patch, acellular scaffolds, extracellular matrix scaffolds, myo-
cardial infarction, heart repair
Introduction
Heart disease remains one of the leading causes ofdeath in industrialized nations with myocardial in-
farction (MI) contributing to at least *20% of the reported
deaths.1 An acute MI occurs when a coronary artery that
feeds oxygenated blood to the right and left ventricles gets
occluded, thus resulting in areas of hypoxia. The hypoxic
environment, if maintained for sufficient amount of time,
eventually leads to cellular death due to lack of oxygen and
nutrients triggering an inflammatory response. The inflam-
matory environment is responsible for the clearing of dead
cells and stimulating neighboring cells to increase matrix
production ultimately leading to scar tissue formation.
The scar tissue that forms after an MI is unable to con-
tract and, due to the high stresses present during the normal
pumping action of the heart, the infarct area deforms over
time leading to myocardial remodeling and reduced cardiac
output. Although reperfusion and pharmacological treat-
ments have shown some improvements in patients after an
MI, the scar tissue is not completely removed and cardiac
output is not restored to pre-MI levels.2 If significant dam-
age is sustained, a heart transplant is a potential treatment
option. However, heart transplantation remains limited by
low availability and the need for life immunosuppression of
the transplant recipient.
Tissue engineering and regenerative medicine principles
provide an alternative approach to restoring myocardial
function after an MI. By combining the expertise of multiple
fields, such as engineering, biology, medicine, biochemistry,
and pharmacology, tissue engineers try to create suitable
tissue replacements capable of restoring function and im-
proving quality of life. This review will first describe the
cellular events that take place after an MI with emphasis on
the host tissue response dominated by inflammatory cells
such as macrophages. The review then will describe how
biomaterials, alone or in combination with a cellular com-
ponent, have been used to engineer suitable myocardium
replacement constructs. Given the complexity of the myo-
cardial tissue, we will also discuss ideas for new advanced
culture systems that can help assemble and test the new
generation of engineered cardiac devices.
Myocardial Infarction
A heart attack or MI is caused by the stenosis and/or
occlusion of a coronary artery leading to improper delivery
of oxygenated blood to regions of the heart. This condition
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is classified based on the extent of occlusion into ST-
Elevation myocardial infarction (STEMI) when occlusion is
completely blocked, or non-ST-Elevation myocardial in-
farction (NSTEMI) when occlusion is not complete. The
physiological and clinical description of MI is described in
details elsewhere2; in brief, the occlusion can affect the
major coronary arteries such as the left anterior descending,
left circumflex, and the right coronary artery. Once the ar-
tery is sufficiently occluded, oxygenation and nutrient deficit
downstream of the occlusion result in the gradual death of
the myocardial tissue (Fig. 1). The infarct site refers to the
portion of the necrotic myocardium that is damaged or in the
process of being damaged by the hypoxic conditions. Most
infarcts involve the death of the full thickness of the ven-
tricular wall (transmural infarction), although in some cases
perfusion from neighboring vessels can help delay and/or
minimize injury. At the early stages of the infarct there is a
decrease in aerobic glycolysis, an increase in anaerobic
glycolysis (accumulation of lactic acid), production of high-
energy phosphates, and reduced contractility.2
Necrosis and apoptosis begin to occur, leading to the acti-
vation of the inflammatory response through the recruitment of
neutrophils and subsequently monocytes from peripheral blood.
Recent studies have shown the active recruitment of circulating
peripheral blood monocytes and a monocyte population resi-
dent in the spleen following an MI.3 In addition, studies have
shown waves of pro- and anti-inflammatory monocytes circu-
lating at different times after the infarct with classically acti-
vated monocytes found soon after the ischemic injury and then
followed by alternatively activated monocytes.4 Once recruited
to the infarct, monocytes differentiate toward macrophages and
begin the labor of removing cellular debris.5,6
During the initial phase of the inflammatory response after
the recruitment of the monocytes, there is a strong presence of
classically activated macrophages or M1 macrophages within
the myocardial tissue. These are macrophages associated with
the removal of pathogens and cellular debris and express
proinflammatory cytokines such as IL-1b, TNF-a, and IL-6.
Thesemacrophages are present at high numbers during the first
week after an infarct in mice with a gradual decrease over
time.4,5,7,8 Following this initial proinflammatory phase, there
is a gradual shift in the type of macrophage toward more al-
ternatively activated macrophages (M2), which are character-
ized by the secretion of CCL-17, TIMP-1, and IL-10. These
macrophages are typically associated with wound healing re-
sponses and are thought to activate fibroblasts, smoothmuscle,
and endothelial cells.5,6,9–11
Myocardial regeneration is the process by which the in-
jured myocardium is restored to its original structure and
function. As described above, the normal healing process
for postinfarction cardiac tissue involves the generation of a
fibrous scar, which provides mechanical support but is devoid
of functional cardiomyocytes. Most treatment strategies focus
on improving the performance of an already damaged tissue
FIG. 1. Diagrammatic representation of an MI. (A) When symptoms of a heart attack are felt, it represents the occlusion
of one or multiple coronary arteries supplying oxygen and nutrients to the heart. (B) Once the artery is occluded, there is
hypoxia due to the limited diffusion of oxygen, resulting in the death of myocardial tissue. Artwork provided by Servier
Medical Arts. MI, myocardial infarction. Color images available online at www.liebertpub.com/teb
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and not in regenerating the myocardium to restore or establish
normal function. More recently, new therapeutic approaches
based on progenitor cells have been developed with the goal
of regenerating tissue to its normal structure and function.
Current Cardiac Treatments
Advancements in medical interventions have improved
the prognosis post-MI considerably, but the incidence of
heart failure is still increasing, likely as a result of the in-
creasing number of patients who now survive the initial
attack. Currently, the only approved treatments for end-
stage heart failure post-MI are left ventricular assist devices
and heart transplantation. The first is plagued by the com-
plications of a chronic external assist device, which include
bleeding (30%), right ventricular failure (20–30%), throm-
boembolism (3–35%), primary device failure (6% -6 months,
64% -2 years), and infection (18–59%).12 The second is a
limited resource in which proper matching of the donor
organ to the patient is a great challenge, limiting even fur-
ther its use. A number of surgical approaches have been
developed as preventative measures to improve patient
survival and their quality of life, and which can be an option
for patients excluded from cardiac transplantation lists. The
most common include angioplasty, left ventricular recon-
struction, and cellular cardiomyoplasty.
Ischemic tissue revascularization
There is agreement that initial treatment for STEMI is
restoring blood flow to the ischemic tissue via tissue re-
perfusion. The main alternatives for reperfusion can be
classified into pharmacologic, surgical, or mechanical. The
pharmacological breakdown of blood clots (thrombus) in
stenotic coronary arteries is known as thrombolysis. The
mechanical alternative to reperfusion is known as primary
percutaneous surgical alternative coronary intervention or
primary coronary angioplasty, where the occlusion is me-
chanically expanded to allow blood flow to resume. The
surgical alternative is known as coronary artery bypass graft
(CABG) surgery, which when compared with angioplasty is
highly invasive (requiring open heart surgery) and requires
extra surgery to obtain the vein graft.
The use of primary angioplasty for the treatment of STEMI
was first described as a rescue treatment in the case of failed
intracoronary thrombolysis and was studied extensively as an
adjunctive therapy. In general terms, the procedure consists of
feeding a deflated balloon or other device (e.g., stent) on a
catheter from the inguinal femoral artery or radial artery up
through blood vessels until they reach the site of blockage in
the heart. At the blockage, the balloon is inflated to open the
artery, allowing blood to flow. Primary angioplasty has been
shown to be more effective to thrombolysis for treatment of
patients with acute STEMI in randomized trials.13–16 The use
of angioplasty requires the procedure to be performed pref-
erably within 90min of the patient presenting to the emer-
gency room, which most hospitals cannot provide.
There is strong evidence that with increasing duration and
severity of ischemia, more cardiac tissue damage can develop,
allowing a variety of reperfusion-associated pathologies,
known as reperfusion injury. This condition results in cardiac
tissue damage through myocardial stunning, microvascular
and endothelial injury, and irreversible cell damage, necrosis,
apoptosis, autophagy, or necroptosis.17,18 Reperfusion injury
has been observed in each of the cardiac tissue revasculari-
zation strategies mentioned above and under certain condi-
tions can be lethal. There are various pharmacological and
nonpharmacological interventions used to reduce reperfusion
injury. In the case of pharmacological interventions, the use
of drugs such as cyclosporine-A, metoprolol, and glucose
modulators has shown some promising results, but a long list
of failed examples makes them a weak alternative. In con-
trast, nonpharmacological interventions have focused on
limiting the infarct size as means to reduce reperfusion injury.
Left ventricular reconstruction
After MI, the formation of scar tissue leads to changes in
left ventricular (LV) size, shape, structure, and physiology
through a process known as myocardial remodeling.19
During this process, there is thinning of the LV walls, with
the elliptical LV becoming more spherical and dilated.20 A
number of different surgical techniques and modifications
have been developed to restore LV shape and reduce its
volume to improve LV function and are collectively known
as LV reconstruction.21–24 This is a specific surgical pro-
cedure developed for the management of heart failure with
LV remodeling caused by coronary artery disease.25 Despite
its success, these procedures have not found general ac-
ceptance in the medical community. Possible reasons in-
clude a lack of robust prospective randomized data showing
the mortality benefit of this technique in patients with is-
chemic cardiomyopathy and dilated ventricles that were
referred for CABG. To address these concerns, the Surgical
Treatment for Ischemic Heart Failure (STICH) trial was
developed to evaluate the role of cardiac surgery in the
treatment of patients with coronary artery disease and LV
systolic dysfunction.26 A major question addressed by this
study was if left ventricular reconstruction improved pa-
tient outcome when combined with CABG. The results of
this clinical trial showed no significant difference between
performing CABG alone or when combined with LV re-
construction.26 These surgical techniques, and the use of
nonbioactive materials as tissue replacements, helped spark
the interest in exploring innovative use of biomaterials and
tissue engineering constructs.
Cellular cardiomyoplasty
Cell transplantation is an area of growing interest in
clinical cardiology, as a potential means of treating pa-
tients after acute MI. Cellular cardiomyoplasty is a thera-
peutic strategy in which progenitor cells are used to repair
regions of damaged or necrotic myocardium. The ability of
transplanted progenitor cells to improve function within the
failing heart has been shown in experimental animal mod-
els and in some human clinical trials.27 The progenitor cells
involved in these new therapeutic approaches include bone
marrow or adipose tissue-derived mesenchymal stem cells
(MSCs), hematopoietic precursor cells, endothelial pro-
genitor cells, endogenous cardiac stem cells, and skeletal
muscle-derived cells.28,29
Three mechanisms have been proposed to describe how
cardiomyoplasty improves myocardial function: (1) transdiffer-
entiation of the administered stem cells into cardiomyocytes,
endothelial cells, and smooth muscle cells,30,31 (2) fusion
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between the stem cell and endogenous cardiac myocytes,32
and (3) release of paracrine factors that stimulate endo-
genous cardiac repair mechanisms.33,34 Conflicting results
showing a lack of transdifferentiation have put into question
its role in cardiomyoplasty and motivated the search of al-
ternative hypotheses like fusion and paracrine signaling.30,35
Further studies suggested that the lack of transdifferentiation
shown was related to differences in experimental proce-
dures, but the exact mechanism remains unknown.36 In
addition, it has been consistently reported that the level of
fusion between stem cells and cardiomyocytes remains
low,32,37 suggesting that additional mechanisms may be
involved. Current results support paracrine signaling as the
principal mechanism for the improvement of myocardial
function. In it, stem cells release cytokines and chemokines
to stimulate other cells into the regenerative process. In fact,
MSCs have been shown to stimulate host myocardial pre-
cursor cells to amplify and differentiate into cardiomyocytes
in vivo.38
The clinical application of cellular cardiomyoplasty for
the treatment of the ischemic tissues after acute MI involves
tissue revascularization, isolation of autologous stem cells
from the patient, and implementation through repeat cardiac
catheterization or intramyocardial injection.39 A major
limitation for the application of cellular cardiomyoplasty as
a treatment option is stem cell retention and engraftment
after intramyocardial implantation.40 A significant propor-
tion of the transplanted cells leak out through the needle
track that is made by the puncturing needle or enter systemic
circulation.41,42 Cell retention is normally less than 10%,
regardless of the delivery route within the first 24 h.43 Al-
though it was initially thought that cell death by apoptosis
was the reason for low engraftment,44,45 it has been dem-
onstrated that venous drainage and the contraction of the
beating heart are the main reasons for cell loss.40,46 Short-
term cell retention is necessary for subsequent long-term
engraftment and cardiac tissue functional improvement after
acute MI. Other unresolved issues include cell delivery
method and route, cell distribution, time transplantation, cell
type, cell number, and viability. There are new therapeutic
approaches involving engineering culture systems, the use
of novel biomaterials for mechanical support of the cells
and for controlled release of therapeutics, and tissue engi-
neering (Fig. 2).
Engineered Cardiac Patch
Engineered cardiac patch is fabricated to mimic the native
extracellular matrix (ECM) and offer mechanical support
and cell delivery into the region of infarction. Its application
helps to limit LV remodeling, prevent dilatation and thin-
ning of the infarct zone, enhance mechanical properties of
ventricle, and reduce cardiomyocyte apoptosis. In addition,
it aids to retain viable transplanted stem cells, which stim-
ulate the formation of vasculature, myofibroblasts, and
cardiomyocytes. Hence, the optimal properties of a scaffold
involve high porosity, microenvironment similar to ECM,
good mechanical properties, biodegradability, and biocom-
patibility. Natural polymers (i.e., collagen, fibrin, chitosan,
alginate, natural ECM, peptides) and synthetic polymers
(i.e., polycaprolactone [PCL], polyglycerol sebacate [PGS],
and polyurethanes) are a choice of materials to fabricate
scaffolds47,48 (Fig. 3). The Tables 1 and 2 summarize some
characteristics of natural and synthetic polymers used for
cardiac patch, respectively.
Acellular biomaterial approach to cardiac repair
Cardiac tissue has limited self-renewal capacity, which
limits its ability to regenerate and repair itself after injury.
Due to the challenges and limitations on the use of bioma-
terials with exogenous cells, acellular injectable biomateri-
als and patches have been evaluated as mechanical supports
for MI. Acellular scaffolds have several advantages com-
pared to cellular scaffolds such as (1) their off-the-shelf
availability for immediate implantation (e.g., SynerGraft,
AlloDerm, DermaMatrix), (2) their limited immune re-
action,49 and (3) low cost and extended shelf life.50 Cardiac
tissue scaffolds should exhibit elasticity matching the
myocardium, host cell integration and vascularization, me-
chanical stability, and nonimmunogenicity to support tissue
function and regeneration. The following sections briefly
discuss the advantages and limitations of major biomateri-
als used as acellular constructs for myocardial repair and
regeneration with emphasis given to naturally occurring
biomaterials.
Collagen. Due to its abundance in connective tissue,
collagen type I scaffolds are increasingly being used in
tissue repair applications. Collagen type I provides a tissue-
like environment for cell attachment and growth, which
facilitates host cell integration. Its main attributes include
biocompatibility, biodegradability, and fibrous contractile
structure.51,52 Collagen type I comprises about 80% of the
collagen matrix in cardiac tissue,53 making it the choice of
preference for cardiac tissue scaffolds. Gaballa et al.54
grafted a three-dimensional (3D) collagen type I scaffold
onto infarcted myocardium in rats and found that the scaf-
fold induced neovessel formation and reduced LV re-
modeling 3 weeks after implantation. However, solid porous
collagen has a lower elastic modulus,55 which can limit its
mechanical integration to the cardiac tissue. Serpooshan
et al. optimized the elastic modulus of collagen type I gel
to improve myocardial contractility in the injured heart.56
Collagen type I was molded using a plastic compression
technique to generate dense tissue scaffolds with a high
elastic modulus. Four weeks post-MI in mice, collagen type
I patches showed host cell infiltration and new blood vessel
formation. Echocardiography showed significant improve-
ment in cardiac function, diminished fibrosis, and inhibition
of LV dilation and wall thinning.
Collagen in combination with other biomaterials such as
chitosan has shown an increase in compression modulus,
which makes it more suitable for the stabilization of the
ventricular wall.57 Incorporation of angiogenic factors, such
as thymosin b4, in composite collagen–chitosan hydrogels
has been shown to induce cell migration and improve an-
giogenesis in vivo.58 Other forms of collagen such as gelatin
have shown good cardiac cell attachment and viability, but
the tensile strength and degradation rates are inferior to
collagen, making it a less attractive option for cardiac tissue
implants. These results indicate that collagen scaffolds can
exert beneficial effects on cardiac remodeling and function
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after injury. Cardiac cell integration and function should be
further evaluated to determine its long-term clinical potential.
Hyaluronic acid. Hyaluronic acid (HA), also known as
hyaluronan, is a natural linear polysaccharide abundantly
found in the ECM of several tissues. Its structure and ligand
binding properties have been linked to angiogenesis59 and
tissue repair.60 Thus, HA has become an important com-
ponent in scaffolds used for tissue repair and regeneration.
In cardiac tissue, HA has shown modest results for cardiac
function recovery postinfarction. Yoon et al. were one of the
first groups that demonstrated the regenerative potential of
HA for heart tissue. A significant decrease in both infarcted
area and apoptotic index as well as an increase in local
FIG. 3. Diagrammatic representation of tissue engineering strategies using cellular and acellular scaffolds. The goal is to
find the optimal configuration that restores myocardial function to preinfarct levels. Color images available online at
www.liebertpub.com/teb
FIG. 2. Diagrammatic representation of the different approaches that can be used to repair infarcted myocardial tissue.
An acellular patch can be used as an off-the-shelf product that can be implanted soon after myocardial infarction. Alter-
natively, cells can be harvested (i.e., progenitor cells) and injected back into the patient. Another approach can be the
isolation of somatic cells (i.e., blood cells), reprogrammed, expanded, differentiated, and assembled into a bioengineered
cardiac tissue that can then be implanted back into the patient as an autologous patch. These approaches have different
timing and expenses associated with them that can have potential impact on their clinical use. Artwork provided by Servier
Medical Arts. Color images available online at www.liebertpub.com/teb
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vasculature were observed in rats injected with an acrylated
HA hydrogel into the epicardium of the infarcted region.61
Similar results have been observed by Abdalla et al. by
evaluating the recovery of cardiac function in the infarcted
heart of rats postinjection of HA gel into the peri-infarct
region.62 Transthoracic echocardiography revealed a sig-
nificant increase of about 18% in ejection fraction in HA-
injected groups compared to the control group. Decreased
collagen deposition and increased levels of VEGF were also
observed supporting reduced scarring and new vasculature
formation in response to HA.
The molecular weight of HA has been shown to affect its
regenerative potential in the myocardium. Evaluation of
different molecular weights of HA-based hydrogels (50,
130, and 170 kDa) showed that the lowest molecular weight
had the most significant regeneration and function recovery
of the infarcted myocardium.63 The regenerative potential of
HA-based hydrogel was markedly reduced in chronic
models of MI, indicating that the injection time is a major
determinant for cardiac repair. The compressive modulus of
HA gels is also an important variable for stabilization of
the infarcted myocardium. Use of hydrogels with high com-
pression modulus (43 kPa) significantly reduced LV re-
modeling and improved function when compared with lower
modulus hydrogel and control groups in an ovine model.64
Due to the increase in wall stress during systole, a high
compression modulus may be more suitable to reduce
myocardial stress distribution. Thus, two major factors,
the molecular weight of HA and injection time, are main
determinants for HA-mediated repair in the infarcted myo-
cardium. Overall, several studies support the use of
HA-based hydrogels as a promising novel therapy to reduce
scarring and promote vasculature formation in the infarcted
myocardium.
Alginate. Alginate is an anionic polysaccharide present
in brown seaweed. It is biocompatible and has been used for
food and pharmaceutical applications.65 Its capacity for in
situ gelation and nonthrombogenic properties makes it at-
tractive for cardiac tissue applications. In heart tissues, in-
tramyocardial injections of alginate hydrogels have shown
significant clinical potential for the improvement of LV
function and reduced remodeling potentially by providing
mechanical support to the damaged ECM. Yu et al. showed
that acellular alginate hydrogels could improve cardiac
function, reduce remodeling, and increase neovascularization
Table 1. Some Natural Polymers for Cardiac Patch
Material Stem cells
Porosity and/or
pore size In vivo model Signaling Ref.
Collagen hMSCs — Male CDF rats a-SMA 118
Autologous stem cells 400–600 mm Male C57/BL6 mouse Anti-sarcomeric actin
antibody and Anti-vWF
121
hMSCs
hESC-MC
— Male athymic RNU
nude rats
CD105, CD73,
Angiogenin, PDGF-B,
VEGF, and CXCL1
105
Autologous
mesenchymal
stem cells
— Wistar rats CD44+, CD90+, CD45-,
CD34-, Desmine, and
a-smooth muscle actinin
119
hESC-derived
cardiovascular
progenitors
Autologous r-ADSCs
— Female Wistar rats
Rowett nude female
rats
Tbx5 and Nkx 2.5 116
Natural ECM BM-MSCs 91.2%– 1.3%;
130.5 – 25.3mm
Male syngeneic Lewis
rats
a-SMA, bFGF, vWF,
PDGF-B, IGF-1, HGF,
MEF2D, MYH6, Type I
collagen, SMMHC,
CD68, and IL-6
139
hMSCs — Adult mongrel dogs Sarcomeric a-actinin,
Atrial natriuretic peptide
Cardiotin, Subunit of the
Cav 1.2, and cardiac
troponin-T
137
Cardiac progenitor cells — — a-MHC, Troponin T,
Troponin C, GATA-4,
nkx 2.5, a-SMA,
Smooth muscle 22a,
Fibroblast-specific
protein 1, vWF, tie2
135
BMMCs 19.5 – 17.9 mm — Sarcomeric a-actinin,
Myosin heavy chain
Cardiac troponin T,
and vWF
134
ADSC, adipose tissue-derived stem cell; ECM, extracellular matrix; hMSC, human mesenchymal stem cell; hESC-MC, human
embryonic stem cell-derived mesenchymal cells; a-SMA, a-smooth muscle actin.
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in a chronic rodent model of ischemic cardiomyopathy.66
The angiogenic effect of alginate can be further enhanced by
incorporating RGD peptides into the biopolymer, but the
structural changes reduce the therapeutic effects of the hy-
drogel.67 Landa et al. evaluated the effect of alginate hydrogel
in the recovery of cardiac function of rats post-MI.68 There
was an increase in scar thickness, and reduced LV systolic and
diastolic dilatation was typically observed even after injection
60 days postinfarction. These results were comparable to
those achieved by neonatal cardiomyocyte transplantation.
The use of alginate hydrogels has also been shown to
improve cardiac function in large animal models. Intra-
coronary injection of alginate hydrogel prevented LV re-
modeling and increased scar thickness in a swine model of
MI.69 The alginate hydrogel was replaced by myofibro-
blasts, which support local tissue restoration while limiting
general myocardial remodeling. Implantation of alginate
hydrogel in dogs with heart failure produced by intra-
coronary microembolizations (LV ejection fraction <30%)
significantly improved ventricular wall stability and func-
tion.70 Injection of alginate hydrogel expanded the LV wall
and improved the LV systolic and diastolic functions at
levels comparable to those observed in dogs in long-term
therapy with beta-blockers.71 These observations motivated
evaluation in patients with ischemic (n= 4) and nonischemic
(n = 2) dilated cardiomyopathy. Patients that received algi-
nate implants showed improvements in LV size and func-
tion as early as 3 days. Reductions in LV volumes and an
increase in ejection fractions were sustained for over 3
months. Due to their promising results, alginate hydrogels
are to date the only and first injectable biomaterial in clinical
trials for treating MI. However, lack of integration between
alginate and cardiac cells might be the major limitation for
tissue regenerative applications.
Chitosan. Chitosan is a cationic hydrophilic polysac-
charide derivate from chitin commonly found in crustacean
shells. It has been extensively used in biomedical applica-
tions, including wound healing,72,73 drug delivery sys-
tems,74 and surgical adhesives.75 The porosity of chitosan
can be controlled as a function of freeze-drying,76 which is
important for host cell migration and tissue integration.
However, chitosan alone is noncell adhesive and has a high
compressive modulus, which requires its chemical modifi-
cation and/or mixing with other biomaterials to obtain op-
timal mechanical and physiological properties for cardiac
tissue. Pok et al. evaluated a multilayered scaffold formed
by a gelatin–chitosan hydrogel around a self-assembled PCL
core for use as a cardiac patch.77 Gelatin and chitosan ratios
of 50:50 and 25:75 significantly improved cell adhesion
while retaining the mechanical strength of PCL. Mixtures of
chitosan and collagen have also shown potential to improve
cardiac function. Deng et al. combined chitosan with col-
lagen to increase the compressive modulus of collagen as a
potential implant for stabilization of the ventricular wall.57
Ahmadi et al. investigated the effects of a collagen chitosan
matrix on cardiac remodeling.78 Mice received local injec-
tion of collagen–chitosan matrix 2 weeks post-MI. LV
ejection fraction was improved only in collagen–chitosan-
treated mice over a 3-week follow-up period. Thus, com-
bination of porous chitosan with lower compressive moduli
and cell-adherent biomaterials may have the potential to
increase tissue integration and therefore increase the me-
chanical stability of the ventricle postinfarction.
Fibrin. Fibrin-based scaffolds are biopolymer gels
formed from fibrinogen, a glycoprotein that contains two
Arginine–Glycine–Aspartic acid (RGD) sequences in each
amino acid chain and is converted by thrombin into fibrin
during blood clot formation simulating the last step of the
blood coagulation cascade.79,80 Fibrin polymerizes in situ
upon the combination of fibrinogen and thrombin. Fibrin
glue has been tested as an injectable scaffold for cardiac
tissue repair. Christman et al. examined the effects of in-
jectable fibrin glue as a scaffold and wall support in the
ischemic myocardium in rats. Fibrin glue alone or with
skeletal myoblasts was injected into the LV 1–2 days after
left coronary artery occlusion. Five weeks after injection,
fibrin glue alone or with cells preserved infarct wall thick-
ness, reduced infarct size, increased blood flow, and im-
proved cardiac ejection function.81,82 Huang et al.
performed a comparative study to determine the therapeutic
potential of fibrin, collagen type I, and Matrigel as injectable
biomaterials for MI repair. Injection of each individual
biomaterial into the infarct zone significantly increased
vascularization compared to the saline solution control
group at 5 weeks post-treatment in rats. The angiogenic
potential was similar for all three polymers probably due the
shared common binding sites for avb3 integrin, which is
associated to angiogenesis. The major disadvantage of fibrin
gels is poor mechanical properties, not able to support the
stresses generated during myocardial contraction.83 There-
fore, fibrin should be combined with other high-compression
moduli components such as chitosan or collagen to increase
mechanical strength and reduce degradation rates.
Decellularized extracellular matrices. Decellularized
matrices are derived from biological tissues in which cells
have been removed, but the architecture and components of
the ECM are preserved. The main advantages of decel-
lularized matrices are preserved structure, size, and com-
ponents of native ECM without the presence of cellular
antigens that could induce an immune reaction.84 In cardiac
tissue studies, decellularized matrices have shown to pro-
mote endothelial cell and cardiac cell infiltration. Decel-
lularized urinary bladder ECM (UB-ECM) has been
evaluated as an epicardial patch for repairing the infarcted
LV.85 At 6–8 weeks postinfarction, pigs received either a
UB-ECM or expanded polytetrafluoroethylene (ePTFE)
patch in the LV. At 3 months, the decellularized matrix was
resorbed showing a highly vascularized tissue enriched in
collagen and myofibroblasts. At the same time point, ePTFE
had a foreign body response and calcification. Similarly,
Robinson et al.85 used a urinary bladder matrix (UBM)
scaffold for repairing the infarcted LV in pigs. Results
showed that after 3 months the constructs had a significant
increase in cardiac marker expression (i.e., a-smooth muscle
actin (SMA)+ myofibroblasts, a-sarcomeric actin, myosin-
HC, tropomyosin, and connexin 43) and the number of
contractile cells (i.e., expressing a-SMA). It has been well
established that UBM scaffolds are superior to synthetic
Dacron in regenerating myocardial tissue. This fact is due to
their potential capacity to promote cardiomyocyte differ-
entiation and/or migration, allowing the ventricular wall to
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approach its normal thickness, and finally resulting in im-
proved regional mechanical function.86,87 Moreover, natural
matrices from small intestine submucosa (SIS)88 and por-
cine sternum89 used in rats models have showed to be a
good alternative to promote angiogenesis, enhance cardiac
function, and decrease apoptosis, through the recruitment of
c-kit+ cells, myofibroblasts, and macrophages after MI. Tan
et al. used a decellularized SIS patch with MSCs on a MI
rabbit model90 and showed significant improvements in LV
function, wall thickness, and vasculature. Decellularized
ventricular and pericardial matrices are two additional op-
tions for MI repair.91–93 Singelyn et al. have shown that
decellularized porcine ventricular tissue can be solubilized
and self-assembled in situ upon injection into myocardial
tissue. Smooth muscle cells and endothelial cells were able
to infiltrate the decellularized matrix both in vitro and
in vivo with a significant increase in blood vessel density.
These studies were performed in the healthy rat myocar-
dium, which have better recovery rates than in MI.
Synthetic materials. Synthetic materials have been
widely used in tissue engineering applications due to im-
proved mechanical properties, material uniformity, and low
risk of infection compared to natural biomaterials. Synthetic
polymers can be modified with high precision to meet
tissue-specific properties such as appropriate degradation
rates, porosity, and mechanical strength. Several synthetic
polymers have been evaluated for cardiac tissue implants,
including poly(ethylene glycol)(PEG), polyvinyl alcohol,
poly(caprolactone)(PCL), polypropylene, polyester, and
poly(N-isopropylacrylamide) (PNIPAM).94,95 Meshes made
of polyester and poly(propylene) have been successfully
used as LV restraints to prevent LV remodeling and dilation
in animal models and human patients.96–100 Injection of a
thermosensitive hydrogel containing PCL and PNIPAM into
the myocardium 4 days postinfarction in rabbits was found
effective to prevent ventricular wall thinning and reduce
systolic and diastolic dilatation after 30 days of treatment.95
Similarly, PEG hydrogels have prevented LV remodeling
and dilation, but lack vascularization unless codelivered
with cells.101 While the mechanical properties and stability
of synthetic polymers are superior to natural polymers, cell
integration is a major limitation. Blends of synthetic and
natural polymers with or without growth factors are often
preferred to support cell migration and tissue replacement of
the implant.102,103
Engineered cellular constructs for cardiac repair
Although acellular scaffolds have many advantages over
cellular scaffolds, the use of cells has also been shown to
improve healing and tissue regeneration. In many cases, the
addition of a cellular component showed improvement over
the material alone.104 The use of an engineered cellular
construct is a therapeutic strategy to regenerate the myo-
cardium lost after an MI by supporting the function of the
myocardium via a mechanically suitable material and the
surviving cells using an appropriate exogenous repair cell.
The cardiac patch is a 3D carrier for cell delivery fabricated
in vitro and implanted over the infarcted tissue47 with the
goals of improving repair cell retention and engraftment,
limiting LV remodeling, preventing LV dilatation and
thinning, enhancing the mechanical properties of ventricle,
and reducing cardiomyocyte apoptosis.48 In addition, it can
also provide the means to stimulate angiogenesis, release of
cytokines, and myocardial perfusion.48,105 All these prop-
erties depend on the choice of scaffold material and repair
cells that will ultimately couple with the native cells.
One of the first patches developed for delivering cells to
an MI site consisted of a cardiomyocyte-enriched extract
from fetal rat ventricular muscle dispersed in a commercially
available gelatin scaffold (i.e., Gelfoam, Merck, Co.).106
Although this cardiac patch showed improved cell survival
and retention, it was not able to demonstrate any improve-
ment in cardiac function. In contrast, a similar type of patch
based on alginate and fetal rat cardiomyocytes showed im-
provement on both cell survival and cardiac function in a rat
MI model.107 This variability in results is common and
needs to be considered. These are mainly due to differences
in degree of injury to the heart due to the infarct procedure
used.108 Additional studies in the development of cardiac
patches have shown a limited use of cardiomyocytes. This is
because these cell types are terminally differentiated, thus
limiting their proliferative capacity.109
As an alternative, many researchers are studying a recently
detected small population cardiac progenitor cells (CPCs)
negative for blood lineage markers (Lin-) and positive for
stem cell surface markers (i.e., c-kit, Sca-1, and MDR-1),
which have the potential for myocardial regeneration.110 A
potential treatment option could be to attract this cell popu-
lation to the infarct site and provide them with the appropriate
environment to stimulate myocardial regeneration. This en-
vironment should promote not only the migration of CPCs
but also of any other cell types that might promote myocar-
dial regeneration (e.g., macrophages, MSCs).
It is important to first differentiate between the term re-
pair, which defines the natural healing process that replaces
the damaged tissue with a scar, and regeneration (our ther-
apeutic objective), in which the damaged tissue rebuilds
itself to its normal structure and function.111 The cardiac
repair process involves an inflammatory response, where
macrophages remove dead cardiomyocytes and secrete an-
giogenic and profibrotic cytokines, chemokines, and prote-
ases.112 This is followed by fibrosis, in which macrophages
and myofibroblasts work together in reinforcing the ven-
tricular wall through the secretion of connective tissue,
eventually forming the scar tissue. This structure is so dense
that it prevents the migration of CPCs, essential for cardiac
regeneration, making fibrosis an important hurdle in mam-
mals’ capacity to regenerate myocardium after MI.113 In
addition, it has been found that acute inflammation is nec-
essary to activate the regenerative response in the neonatal
mouse heart.114
Another type of progenitor cells that have been tested for
myocardial regeneration are MSCs loaded into scaffolds
made of natural and synthetic polymers.115 Collagen, fi-
brin, PGS, PCL, nanopeptides, polyurethane (PU), and 3-
hydroxybutyrate-co-4hydroxybutyrate [P(3HB-co-4HB)] are
examples of these scaffold biomaterials. The use of these
patches has shown increased vascularization and improve-
ment in cardiac function. They are also an improvement over
cellular cardiomyoplasty, which is limited because in this
technique cell survival involves enzymatic cell dissociation
before injection and because of the poor vascularization in
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the infarct site.116 Cardiac patches could overcome these
limitations by retaining viable transplanted stem cells in a
scaffold that would facilitate cell migration and cell adhe-
sion toward the infarcted area.48 In addition, these trans-
planted cells could stimulate formation of vasculature and
cardiomyocytes. As with most of the cell-bearing scaffolds,
optimal properties of these include high porosity, high
surface area to volume ratio, microenvironment similar to
natural ECM, good mechanical properties, biodegradability,
and biocompatibility.47,117 These parameters can be mod-
ulated with the choice of materials used and the synthesis
conditions chosen for its fabrication.
Collagen. Collagen matrices loaded with MSCs have
proven to be a good alternative biomaterial for cardiac
patches. Simpson et al. used collagen matrices seeded with
human MSCs (hMSCs) to treat MI in the male CDF rat
model.118 The results showed that the application of this
patch promoted myocardial regeneration and induced the
expression of a-SMA marker, which was associated with an
increase in myofibroblasts within the infarct region. Like-
wise, Maureira et al. developed a cardiac patch based on
collagen and autologous MSCs, which was implanted in an
MI rat model.119 The results of this study showed reverse
remodeling of the infarcted area, improvement of perfusion,
a reduced infarction, an increase of ventricular wall thickness,
enhanced angiogenesis, and formation of myofibroblast-like
tissue.
Similarly, the effectiveness of collagen seeded with adi-
pose tissue-derived stem cell epicardial patches to preserve
LV function, decrease fibrosis, and increase vessels in the
infarct area was confirmed in reported studies.116 Further-
more, studies have evaluated the response of collagen ma-
trices seeded with hMSCs and human ESC-derived
mesenchymal cells (hESC-MC) to repair the infarcted
myocardium of athymic nude rats.105 This in vitro study
showed similar responses with regard to stem cell potency,
viability, and cell proliferation for both cell types, while the
results from the in vivo study demonstrated maintenance of
the diastolic function and attenuated adverse LV remodel-
ing. Interestingly, even with the observed differences in
response to secreted paracrine factors, local angiogenic ef-
fects were seen in both cell types. Shi et al. demonstrated
that collagen scaffolds covalently conjugated with the Sca-1
antibody (present in adult murine hematopoietic stem
cells120) can attract native autologous stem cells to en-
courage cardiomyocyte regeneration after MI.121 In another
study, collagen I patches seeded with human bone marrow
CD133+ cells were used on cryoinjured rat hearts to assess
their in vitro and in vivo cardiomyocyte differentiation po-
tential.122 Results showed a capacity to induce angiogenesis,
but not to induce cell differentiation. In a similar type of
study, a collagen type I patch seeded with human umbilical
cord blood mononuclear cells was used in MI mouse model
to assess their cardiomyocyte differentiation potential.123
These patches showed improvements in vascularization and
cardiac function, as measured by an increase in ejection
fraction. The same group also conducted the Myocardial
Assistance by Grafting a New Bioartificial Upgraded
Myocardium (MAGNUM) phase I clinical trial using the
same autologous cell-seeded patches.124 Ten patients pre-
senting LV postischemic myocardial scars that were un-
dergoing CABG had the seeded patches fixed onto the
ischemic tissue. Results showed that the patch increased the
LV wall with viable tissue and helped normalize cardiac
wall stress in injured regions, improving diastolic function.
Fibrin. Fibrin is a hydrogel that contains adhesion mol-
ecules and has been shown to be biocompatible. However,
fibrin-based scaffolds must be stabilized with other materi-
als to compensate for their rapid reabsorption.125,126 Studies
demonstrate the feasibility of applying injectable fibrin gels
into the infarcted myocardium.127,128 Recently, Bago et al.
observed cardiomyogenic differentiation of adipose tissue-
derived progenitor cells using fibrin scaffolds in a mouse
model.129 This system promoted endothelial lineage, in-
creased vessel density, improved cardiac function, and di-
minished scar size after MI. Wendel et al. reported infarct
size reduction, elimination of LV wall thinning, vasculari-
zation, and the restoration of cardiac function in rats 4 weeks
after transplantation of the cardiac patch, which consisted
of fibrin scaffolds seeded with neonatal rat cardiac cells.48
Geuss et al. showed PEGylated fibrin gels as an alternative
to promote proliferation and cardiomyogenic differentia-
tion.126 However, by comparing two-dimensional (2D)
versus 3D cell cultures, contractile activity was maintained
when cells were cultured on layers of PEGylated fibrin and
significantly reduced when cultured as aggregates. The au-
thors argued that the lack of contractility was related to low
cardiomyocyte proliferation and not to the influence of
mechanical properties (i.e., elastic modulus).
To develop cardiac patches that more closely mimic
ECM, current tissue engineering approaches to myocardial
regeneration are implementing the use of therapeutic genes
to enhance paracrine action. An example, insulin-like
growth factor-1 (IGF-1), which is a hormone that has been
shown to enhance cardiac differentiation, reduces apoptosis
and enhances neovascularization.79,130,131 Recently, Li et al.
published the first study showing cardiac repair in a large
animal model using fibrin patch seeded with IGF-1-modified
MSCs.79 The results of this study were interesting because,
despite the absence of cardiomyogenic differentiation
in vivo, it promoted cardiac repair through other pathways.
Similarly, Ye and colleagues used three cell types: human
iPSC (hiPSC)-derived cardiomyocytes, endothelial cells,
and smooth muscle cells in combination with fibrin patches
seeded with IGF-1-encapsulated microspheres to treat MI in
a porcine model.132 The results demonstrated cardiac repair
without developing ventricular arrhythmias. In addition,
Xiong et al. seeded fibrin patches with hESC-derived en-
dothelial and smooth muscle cells and implanted on a por-
cine MI model.133 Results after 7 days showed a significant
improvement in LV ejection fraction, which was maintained
for over 4 weeks.
ECM scaffolds. An innovative alternative that has pro-
ven very effective is the use of natural matrices as scaffolds.
Wang et al. demonstrated that a cardiac patch consisting of
decellularized porcine myocardium seeded with porcine
bone marrow MSCs can support cardiomyogenic differen-
tiation and angiogenesis in vitro (Fig. 4A).134 In addition,
decellularized human myocardium was seeded with human
mesenchymal progenitor cells suspended in a fibrin hydro-
gel and fixed on the MI tissue in a nude mice model.104
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Results showed a significant improvement in cardiac func-
tion and vascularization. French et al. indicated that CPCs
seeded on naturally derived cardiac ECM show enhanced
adhesion, maturation, proliferation, and survival compared
with a collagen matrix.135 Singelyn et al. used porcine
myocardial tissue as an injectable myocardial matrix into rat
myocardium.91 The results demonstrated that this matrix not
only allowed the formation of nanofibrous structures con-
taining glycosaminoglycans but also the migration of en-
dothelial and smooth muscle cells. The feasibility of this
FIG. 4. (A) Decellularized porcine myocardium can support cardiomyogenic and angiogenic differentiation. (a) Large pores
evenly distributed across the 2mm thick acellular scaffold (H&E). (b) Edge to edge view of thorough recellularization at 2
weeks in which cells were found to infiltrate and distribute within the myocardial scaffold. (c) Tissue remodeling was observed
in the 4-week recellularization tissue construct; cells were still observed, and cell density was found higher than of the 2
week’s construct. Reprinted with permission from Wang et al.134 (B) Immunofluorescence images showing the expression of
cardiomyocyte markers, a-actinin, ANP, and MHC in CPCs that have been induced to differentiate 21 days after seeding onto
PCL or PCL–TCNT meshes, or TCP. Scale bar, 50mm. Reprinted with permission from Wickham et al.150 ANP, atrial
natriuretic peptide; CPC, cardiac progenitor cell; MHC, myosin heavy chain; TCP, tissue culture plastic. Color images
available online at www.liebertpub.com/teb
FIG. 5. Summary of engineered approaches to cardiac tissue regeneration. Extracellular matrix materials such as collagen,
alginate, hyaluronic acid, and chitosan are used alone or combined as a cardiac patch to provide mechanical strength and
stabilize the ventricular wall (acellular). Addition of cells to extracellular matrix constructs (cellular) or engineered matrices
improves cardiac function and vascularization compared to acellular models. The question mark (?) implies it remains to be
determined in future studies. Color images available online at www.liebertpub.com/teb
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approach was demonstrated in a large animal model through
a transendocardial catheter injection.136
Extracellular matrices derived from porcine UBM can
also serve as an inductive scaffold for myocardial repair.
Potapova et al. found formation of myocytes and improved
mechanical function in canine heart using UBM seeded with
partially differentiated hMSCs.137 Shah et al. also probed
the ability of this natural matrix to support and promote the
growth of mature cardiomyocytes.138 In addition, Wei et al.
used decellularized bovine pericardial tissue as scaffolds
seeded with multilayered MSCs on a male syngeneic Lewis
rats MI model.139 The advantage of this study was the de-
velopment of vasculogenesis, angiogenesis, and differenti-
ation of MSCs toward myofibroblast, although no mature
cardiomyocytes were found within the patch.
Poly (glycerol sebacate). In 2002, Langer and coworkers
reported the synthesis of PGS, a biodegradable elastomer
composed of glycerol and sebacic acid with desirable che-
mical and physical properties for tissue engineering appli-
cations.140 In addition, this polyester is considered a good
material for cardiac patches because of its biodegradability,
excellent mechanical properties, and low cost.141–143 Chen
et al. used PGS patches to deliver differentiated cardio-
myocytes from hESCs to treat MI in adult male Sprague
Dawley rats.144 The results showed that this system not only
maintained active cardiomyocytes beating for an extended
time but it also supported cells during in vivo implantation.
In addition, the PGS/fibrinogen cardiac patch has demon-
strated excellent mechanical properties, good cell–scaffold
interactions, and capacity to stimulate the expression of
cardiac-specific markers (i.e., a-actinin, troponin, ß-myosin
heavy chain, and connexin 43).145 In addition, PGS/fibrinogen/
VEGF scaffolds loaded with MCSs have been shown to
promote both the expression of cardiac and endothelial cell
markers while preventing negative ventricular remodeling
in vivo in a porcine MI model.117 Likewise, it was demon-
strated that PGS/collagen patches can provide a good local
microenvironment similar to the natural interactions exist-
ing between cells and the native ECM, stimulating cardio-
genic differentiation of MSCs.146
Polycaprolactone. PCL is a FDA-approved biodegrad-
able synthetic polymer used as a scaffold material for car-
diac tissue regeneration due to its mechanical properties and
biodegradability. Nevertheless, PCL must be combined with
other polymers (e.g., dextran, poly-vinylalcohol, and poly-
ethylene oxide) to improve its hydrophobicity through the
presence of ester and keto groups in its structure, which
inhibit cell binding.147 Therefore, electrospun nanofibrous
scaffolds fabricated from this material can simulate the
ECM microenvironment, allowing diffusion of nutrients,
cell adhesion, cell growth, migration, proliferation, and
differentiation.148 Studies have reported that the use of a
PCL/oligomer hydrogel can simulate ECM.149 The incor-
poration of thiophene-conjugated carbon nanotubes into
PCL scaffolds enhances the mechanical properties, cell ad-
hesion, proliferation, and differentiation of CPCs (Fig. 4B).150
Similarly, in vivo studies in rats have demonstrated that
PCL/gelatin scaffolds loaded with MSCs can restrain LV
remodeling, improve cardiac function, and promote both an-
giogenesis and cardiomyogenesis in the infarcted area.47 In
addition, scaffolds of the PCL derivative poly(glycolide-co-
caprolactone) were seeded with bone marrow mononuclear
cells and fixed in a rat MI model.151 Results after 4 weeks
showed significant improvements in ejection fraction, ven-
tricular diameter, and hemodynamics.
Others. Research in the development of cardiac patches
has also explored other polymeric materials. For instance, a
commercial biological matrix (cell-PuraMatrix) formed of
self-assembled peptides can serve as a biological scaffold to
evaluate the feasibility of different types of cells involved in
myocardial repair in mice [(i.e., clonal stem cell antigen-1-
positive cardiac progenitors (cSca-1), bone marrow mono-
nuclear cells, skeletal myoblasts, and adipose tissue-derived
MSCs)]. Results indicate that cSca-1 is better in preventing
cardiac remodeling and systolic dysfunction compared to
the other cell types.152 In vitro and in vivo studies have
demonstrated that [P(3HB-co-4HB)] and PU can support
stem cell growth,153 while a cardiac patch consisting of
hMSCs encapsulated in alginate and seeded in polyethylene
glycol hydrogels stimulates healing after a heart attack.154 In
addition, Miyagi et al. developed a hybrid scaffold using a
gelatin scaffold (i.e., Gelfoam, Merck, Co.) coated with PCL
(for reinforcement) and seeded with bone marrow MSCs
and the cytokine stem cell factor and stromal cell-derived
factor-1alpha.155 Results in a small animal ventriculotomy
model showed a significant improvement in cardiac func-
tion when compared to controls (i.e., animals and unmodi-
fied gelatin sponge). This improvement was observed in
all groups with the scaffold alone, with or without cytokines
or cells.
Advanced Culture Systems
Appropriate cell function and tissue integration depend on
cell–cell and ECM interactions. In the myocardium, elec-
trical stimuli are propagated through interconnected cardi-
omyocytes highlighting the importance of gap junctions and
cell polarization for appropriate function. Intercellular
communication between cardiomyocytes is essential for the
coordinated and synchronized contraction of the cardiac
muscle. This communication occurs through gap junctions,
which are membrane channels formed by the connexin
family proteins which allow the propagation of rapid an-
isotropic impulses. These connexins have been shown to
play a crucial role in determining impulse conduction and
the heart morphogenesis, as well as in several cardiomy-
opathies, such as myocardial ischemia.156 In vitro, cell po-
larization and cell–cell interconnectivity can be achieved
by modulating cell adhesion to the culture surface. In this
section, we discussed current engineered techniques used
to develop optimal ECM architecture and improve cardiac
cell–cell adhesion and function.
Electrospinning nanofibers
Electrospinning is a technique that uses an electrical
charge to produce nanofibers from polymer solutions. This
technique has gained a lot of popularity for tissue engi-
neering applications due to its ability to produce a network
of interconnected nanofibers with similar fibrous architec-
ture to natural ECM found in soft tissues. Several biocom-
patible and biodegradable polymers have been used to
develop nanofiber networks using the electrospinning
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technique for cardiac tissue regeneration applications. Zong
et al. used electrospinning to fabricate biodegradable non-
woven poly(lactide)- and poly(glycolide)-based (PLGA)
scaffolds.157 In these polymeric fibers, primary cardiomyo-
cytes developed mature contractile machinery (sarcomeres)
and showed electrical activity using voltage-sensitive dyes
over 7 days. Similar cardiomyocyte contractility and sur-
vival have been observed with other biodegradable poly-
mers used in electrospinning, such as polyurethane,158
poly(lactic-co-glycolic) acid (PLGA),159 and PCL.160
However, these in vitro studies were carried out in the ab-
sence of fibroblasts, which can modulate cardiomyocyte
function and structure161 and thereby impact long-term
survival and tissue integration. Hussain’s group addressed
the fibroblast gap in 3D cardiac tissue constructs by fabri-
cating a 3D chitosan nanofiber scaffold using an electro-
spinning technique to maintain cardiomyocyte function with
fibroblast cocultures.162 A mat of chitosan fibers (*150mm
thick) was coated with fibronectin to enhance cell adhesion
of neonatal cardiomyocytes isolated from rats in coculture
with 3t3-J2 fibroblasts. Cardiomyocyte cocultures main-
tained cell polarization and expressed high levels of Con-
exin43, a gap junction protein required to propagate
electrical stimuli, over 3 weeks. Image analysis of intra-
cellular calcium ion staining showed that cardiomyocytes
maintained an elongated morphology and beating frequency
of 17 – 3 contractions per minute only in 3D cocultures, but
not in 2D or 3D monocultures highlighting the importance
of fibroblasts for long-term function in cardiac tissue con-
structs. Overall electrospinning techniques have shown great
potential for heart tissue scaffold. However, in vivo studies
are needed to evaluate heart function and recovery over time
following MI.
Engineered cell sheets
Cells sheets have improved cell survival compared to
single cells injected in tissues163 and have been used clini-
cally for the repair of several tissues such as eye cornea,164
cartilage,165 and heart.166 Cell sheets are formed by de-
tachment of 2D cell monolayers using surface detachable
polymers or magnetic particles. Okano and colleagues de-
velop a method to harvest cell sheets by lowering the culture
temperature, using the temperature-responsive polymer
poly(N-isopropylacrylamide) (PIPAAm).167 When cova-
lently grafted on the surface of culture dishes, cells adhere
via serum and cell membrane proteins, due to PIPAAm
hydrophobicity at the standard culture temperature of 37C.
Below its critical temperature of 32C, PIPAAm becomes
very hydrophilic and protein nonadhesive; thus, at lower
temperatures, cell sheets detach without damaging cell–cell
junctions or ECM proteins underneath the cell sheets. Using
this method, Okano and colleagues fabricated a 3D sheet of
pulsatile neonatal rat cardiomyocytes.167 The multilayer
cardiac construct was macroscopically observed to pulse
spontaneously and showed a diffuse pattern of Connexin 43
gap junctions. Long-term survival was observed up to 1
year, and the cell sheet construct showed well-differentiated
sarcomeres and abundant mitochondria.168 Usually thick
cell sheets (>300mm) are preferred for tissue transplant, but
limited due to lack of sufficient vascularization. To over-
come this limitation, Okano’s research group explored the
possibility of adding endothelial cells to the 3D contractile
constructs.169 Cell sheets were stacked and transplanted into
the dorsal subcutaneous tissue of rats. One week after
transplantation, fluorescence-labeled endothelial cells in the
stack formed continuous tubular blood vessel networks in
the construct and integrated with the underlying host tissues.
The myocardial endothelial tissue grafts showed improved
vascularization compared to myocardial cell sheets that can
potentially overcome the limits of mass transport to create
functional integrated tissues. However, these studies were
carried out in subcutaneous tissue rather than in damaged
heart tissue; thus, results may not fully reflect their potential
for myocardial repair.
Sawa’s group evaluated the use of myoblast sheets for
treatment of MI. Two weeks after MI, cell sheets were
directly implanted over the scar area and heart function
was monitored. Myoblast sheet MI-treated group demon-
strated uniform repair in the anterior wall and improved
function probably due to remodeling of the geometry of the
LV chamber. In addition, myoblast sheets showed higher
secretion of proangiogenic factors HGF and VEGF com-
pared to single cell injection and controls.168 In another
study, clinical implantation of autologous myoblast sheets
in a patient who had been supported with a LV assist
system for dilated cardiomyopathy showed significant
improvement.170
Another strategy termed magnetite force-based tissue
engineering has been successfully used to generate cell
sheets for tissue engineering applications.171,172 This
method uses a magnetic field to generate sheets of mag-
netized cells. Liposomes are loaded with magnetite to
display a positive charge that electrostatically fuses with
the cell membrane. Cells are grouped to form sheets by
placing a magnet at the bottom of a cell culture well. Ishii
et al. used this technique to implant a multilayered sheet of
adipose-derived regenerative cells (ADRC) in the infarcted
myocardium.173 After 28 days of implantation, echocar-
diographic measurements revealed that the decreases in
LVFS and LVEF following MI had significantly improved
in ADRC sheets compared to collagen gel and ADRC
controls. One of the main advantages of this cell sheet
technique is the improvement in angiogenesis more ef-
fectively than direct injection of cell suspensions, which
can explain the observed significant decrease in cardiac
fibrosis and increased myocardial capillaries, compared
with the control groups. One major drawback in this study
is that ADRC sheets were placed on the surface on the
infarcted myocardium after 1min of coronary occlusion,
which could have contributed to the decrease of adverse
remodeling as necrotic tissue is minimal. Cell death can
occur as quickly as 20min after coronary artery occlusion,
which is within the time frame of MI, and can negatively
impact the regenerative potential of the tissue. Thus, ad-
ditional studies with various times of sheet implantation
are required to determine the potential of these cell sheets
for cardiac regeneration.
Multicellular constructs and advanced culture systems
As our understanding of the architecture and composition
of myocardial tissue increases, it becomes apparent that a
single cell type-based tissue engineering approach may not
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be sufficient to repair the myocardium. Two culture and
triculture systems might be required to provide the appro-
priate combination able to improve cell coupling with the
host’s cells and ultimately improve function. This will also
require a new 3D culture system to recapitulate the ultra-
structural composition and orientation of the myocardium
while allowing for proper diffusion of nutrients and cell
survival. The only cell sources that can reproducibly provide
functional cardiomyocytes in vitro are pluripotent stem cells
(ESCs and iPSCs). Although these cells provide functional
myocytes, when assembled into 3D tissues an optimal ratio
of supporting cells (such as fibroblast) is needed for the
formation of myocardial-like tissue.174 As shown in previ-
ous sections, the infiltration of these supporting cells is a
requirement for a viable scaffold. For instance, the combi-
nation of cardiomyocytes with endothelial cells and mes-
enchymal cells has been shown to improve contractility
in vitro, further supporting the role of multiple cells during
the formation of engineered tissues.175 Another level of
complexity that will need to be added is the incorporation of
biophysical stimulation. This has been reviewed else-
where,176,177 but will be needed to improve the function and
maturity of cardiac constructs in vitro.
Another interesting approach has been to decellularize
whole organs to provide the best 3D environment for cells to
attach and grow in their appropriate in vivo compart-
ments.178,179 The work by Wang et al. is a good example, in
which a 2-mm section of porcine myocardium was reseeded
with differentiated bone marrow mononuclear cells.134 This
scaffold maintained the cardiomyocyte-like phenotype of
the seeded cells and showed angiogenesis potential and re-
covery of the native tissue’s mechanical properties after
remodeling. Knowing the extent of recapitulation of the
native structure or the correct combination of cells needed to
provide physiologically relevant bioengineered tissues still
remains to be determined. It is clear that although some
cardiomyocyte 2D culture systems have proved adequate for
gathering cardiac physiological data in applications such as
drug discovery,180 these are not adequate for tissue regen-
eration applications, where the in vivo tissue complexity
needs to be recapitulated. Future culture systems should
advance toward 3D cultures providing appropriate bio-
physical conditions and oxygen tension to support native-
like bioengineered cardiac tissues for implantation.
In addition to creating tissues in the laboratory, it is also
important to test such constructs under physiologically rel-
evant conditions. The traditional approach has been to test
cardiac patches in animal models (often in small animal
models). This approach provides information regarding
survival of the cardiac repair cells, but remains a poor model
when testing human-derived cells given the physiological
differences between rodents and humans and the need for
immune-compromised animals. The development of in vitro
culture systems that use relevant cells during the host tissue
response such as macrophages to test bioengineered cardiac
tissues has been proposed.9–11 As explained in previous
sections, after an MI there is a dynamic response driven by
different subtypes of macrophage (proinflammatory vs.
prohealing), which play a major role during the remodeling
process. However, the interactions between inflammatory
cells and engineered cardiac patches have been widely ig-
nored during in vitro screenings. A recent study by Pallotta
et al. showed that there is potential cross talk between
the macrophage subtype and cardiomyocytes derived from
human ESCs further supporting the need to understand these
interactions.181 Advanced culture systems that incorporate
the host tissue response and repair cells will allow for
the manufacture and screening of bioengineered cardiac tis-
sues that can be more readily translated to clinical use. The
main advantages and challenges of the different approaches
to cardiac tissue regeneration are summarized in Figure 5.
Conclusions and Future Directions
Engineering approaches toward the repair of myocardial
tissue have shown promise in the past, but full restoration of
myocardial function remains elusive. As our understanding
of the heart’s physiology and function grows, tissue engi-
neering principles can be applied toward the design of an
engineered cardiac patch that ultimately restores function to
the heart and prevents myocardial wall remodeling. Among
the potential approaches are (1) acellular scaffolds that
provide biological activity and biophysical support to the
heart and (2) cellular scaffolds that provide the minimum
combination of cells and biomaterial composition needed
for increased biological activity and biophysical support. It
is also clear that advanced culture systems (i.e., triculture
systems) will be needed to create more advance engineered
cardiac tissues and to create better screening tools to test
bioengineered cardiac patches in vitro.
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